The melanoma vaccine succeeded in the large trial: so why are investors sour?
The personalized vaccine addition from Moderna and Merck to Kitrida led to a 42% reduction in the risk of melanoma recurrence or death, with relatively mild side effects. The companies are already preparing to file for approval in the U.S., and anticipate a launch in 2027. Melanoma expert Dr. Michael Postov: "Something we really haven't seen before."



